WHO says wider alert on contaminated J&J cough syrup ‘likely’

The World Health Organization is likely to issue a wider warning about contaminated Johnson and Johnson-made children’s cough syrup found in Nigeria last week, it said in an email. Nigeria’s regulator recalled a batch of Benylin syrup last Wednesday, having found a high level of diethylene glycol in the product during routine testing. The contaminant, … Read more

Stock market today: Live updates

Planet Fitness stock slips after naming new CEO Shares of Planet Fitness were nearly 4% lower on Tuesday after the company announced Colleen Keating would assume the CEO role effective June 10. Stock Chart IconStock chart icon Planet Fitness stock. Keating comes to Planet Fitness after serving as chief executive of FirstKey Homes since 2020. … Read more

Johnson & Johnson (JNJ) earnings Q1 2024

An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Tuesday reported first-quarter adjusted earnings that topped Wall Street’s expectations as sales in its medical devices business surged. Meanwhile, the company’s total revenue for the … Read more

Neutrogena is closing Los Angeles office, laying off workers

By Bloomberg Published Apr 11, 2024 ​Neutrogena is permanently closing its Los Angeles office as parent Kenvue Inc. consolidates operations to New Jersey. Bloomberg The closure is resulting in 84 layoffs, according to a worker notification document viewed by Bloomberg News. Of those employees, 74 have been offered relocation and employment at other company locations. Kenvue, which … Read more

J&J cell therapy gains edge over Bristol Myers rival

Jonathan Raa | Nurphoto | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Hi folks! Two competing cell therapies from Bristol Myers Squibb and Johnson & Johnson both got good news from the Food and Drug Administration on Friday.  But J&J’s drug is … Read more

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the Phase 3 CARTITUDE-4 study, in which treatment with CARVYKTI® in 1-3 prior lines of therapy reduced the risk of disease progression or death … Read more

We’re buying more of this health-care company amid an overdone sell-off

Shortly after the opening bell, we will be buying 140 shares of Abbott Laboratories at roughly $112. Following the trade, Jim Cramer’s Charitable Trust will own 700 shares of ABT, increasing our weighting in the portfolio to 2.42% from 1.95%. We are buying more Abbott Laboratories into its recent weakness as we continue to believe … Read more

Jim Cramer defends Elon Musk’s use of ketamine for depression

CNBC’s Jim Cramer said Tuesday that Elon Musk’s disclosure that he takes prescription ketamine for depression was courageous and “saved a lot of people from killing themselves.” “I defend him as much as possible because there are many people who would never be brave enough to admit they take this drug,” Cramer said on ” … Read more

Nvidia and Johnson & Johnson to build AI applications for surgery

The New York Stock Exchange welcomes Johnson & Johnson. NYSE Johnson & Johnson on Monday announced it is working with Nvidia to develop and scale new artificial intelligence applications for surgery.  J&J’s MedTech unit and Nvidia plan to integrate AI within devices and platforms from pre-op to post-op to help ensure that surgeons have access … Read more

What’s next in Medicare drug price negotiations

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services building in Washington, D.C., on Oct. 6, 2022. Anna Moneymaker | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! The bitter legal battle … Read more